María
Abáigar Alvarado
Ikertzailea 2020-(e)tik
Argitalpenak (22) María Abáigar Alvarado argitalpenak
2021
-
Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients
Annals of Hematology, Vol. 100, Núm. 8, pp. 1995-2004
-
Co-occurrence of cohesin complex and Ras signaling mutations during progression from myelodysplastic syndromes to secondary acute myeloid leukemia
Haematologica, Vol. 106, Núm. 8, pp. 2215-2223
-
Multicenter Next-Generation Sequencing Studies between Theory and Practice: Harmonization of Data Analysis Using Real-World Myelodysplastic Syndrome Data
The Journal of molecular diagnostics : JMD, Vol. 23, Núm. 3, pp. 347-357
-
NEMHESYS - European Perspective on the Implementation of Next-generation Sequencing Into Clinical Diagnostics
HemaSphere, Vol. 5, Núm. 3, pp. E541
2020
-
Genome-wide transcriptomics leads to the identification of deregulated genes after deferasirox therapy in low-risk MDS patients
Pharmacogenomics Journal, Vol. 20, Núm. 5, pp. 664-671
-
Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia
British Journal of Haematology
2019
-
CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase
Leukemia, Vol. 33, Núm. 2, pp. 518-558
-
Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation
Annals of Hematology, Vol. 98, Núm. 9, pp. 2151-2162
2017
-
A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblasts
Leukemia Research, Vol. 56, pp. 82-87
-
Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia
British Journal of Cancer, Vol. 117, Núm. 2, pp. 256-265
-
Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes
Oncotarget, Vol. 8, Núm. 63, pp. 106948-106961
2016
-
Chromothripsis is a recurrent genomic abnormality in high-risk myelodysplastic syndromes
PLoS ONE, Vol. 11, Núm. 10
-
Genome-Wide DNA Copy Number Analysis of Acute Lymphoblastic Leukemia Identifies New Genetic Markers Associated with Clinical Outcome
PloS one, Vol. 11, Núm. 2, pp. e0148972
-
Identification of expression patterns in the progression of disease stages by integration of transcriptomic data
BMC Bioinformatics, Vol. 17
2015
-
ACGH-MAS: Analysis of aCGH by means of multiagent system
BioMed Research International, Vol. 2015
-
Deregulation of genes related to iron and mitochondrial metabolism in refractory anemia with ring sideroblasts
PLoS ONE, Vol. 10, Núm. 5
-
Fluorescence in situ hybridization analysis does not increase detection rate for trisomy 8 in chronic myelomonocytic leukemia
Leukemia and Lymphoma
2013
-
Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): A study on 852 patients
Leukemia
-
Prognostic impact of the number of methylated genes in myelodysplastic syndromes and acute myeloid leukemias treated with azacytidine
Annals of Hematology, Vol. 92, Núm. 11, pp. 1543-1552
-
Single nucleotide polymorphism array karyotyping: A diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing
Genes Chromosomes and Cancer, Vol. 52, Núm. 12, pp. 1167-1177